


Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project

Rafael Marcos-Gragera,¹ Claudia Allemani,² Carmen Tereanu,² Roberta De Angelis,³ Riccardo Capocaccia,³ Marc Maynadie,⁴ Stefano Luminari,⁵ Stefano Ferretti,⁶ Tom Børge Johannesen,⁷ Risto Sankila,⁸ Marja-Liisa Karjalainen-Lindsberg,⁹ Arianna Simonetti,³ Maria Carmen Martos,^{10,11} Martine Raphaël,¹² Pilar Giraldo,^{11,13} the HAEMACARE Working Group, and Milena Sant^{2,14}

¹Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health and Catalan Institute of Oncology, Girona, Spain; ²Analytical Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³National Centre for Epidemiology, Surveillance and Health Promotion, Department of Cancer Epidemiology, Istituto Superiore di Sanità, Rome, Italy; ⁴Côte d'Or Haematological Malignancies Registry, EA 4184, University of Burgundy, Dijon, France; ⁵Department of Oncology and Haematology and Modena Cancer Registry, University of Modena and Reggio Emilia, Modena, Italy; ⁶Ferrara Cancer Registry, Pathology Section, Department of Experimental and Diagnostic Medicine, Ferrara University, Italy; ⁷Department of Clinical and Registry-Based Research, The Norwegian Cancer Registry; ⁸Finnish Cancer Registry, Helsinki, Finland; ⁹Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland; ¹⁰Center for Public Health Research, Valencia, Spain; ¹¹Cancer Registry of Zaragoza, Aragon Institute of Health Sciences, Zaragoza, Spain; ¹²Department of Haematology, Le Kremlin-Bicêtre, University Paris-Sud, France; ¹³Department of Haematology, Hospital Universitario Miguel Servet, Zaragoza, Spain; ¹⁴HAEMACARE Project Leader

Citation: Marcos-Gragera R, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Maynadie M, Luminari S, Ferretti S, Johannesen TB, Sankila R, Karjalainen-Lindsberg M-L, Simonetti A, Martos MC, Raphaël M, Giraldo P, the HAEMACARE Working Group, and Sant M. Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project. *Haematologica* 2011;96(5):720-728. doi:10.3324/haematol.2010.034264



Online Supplementary Figure S1. Age-specific period estimates of 5-year relative survival of patients with lymphoid neoplasms diagnosed in 2000-2002, and grouped according to HAEMACARE.

Online Supplementary Table S1. Distribution by sex, age at diagnosis and European region of patients with lymphoid neoplasms diagnosed in 1995-2002 from 41 cancer registries included in the survival analyses.

ICD-O-3 Morphology Code	N. cases	Distribution by age (%)				Distribution by European region (%)				
		0-14	15-49	50-69	70-99	Northern Europe	UK and Ireland	Central Europe	Southern Europe	Eastern Europe
Hodgkin lymphoma, total	12,405	5.2	63.8	19.7	11.3	7.7	8.5	8.9	8.6	13.2
9659 Nodular lymphocyte predominant Hodgkin's lymphoma	360	9.1	60.0	23.1	7.8	0.5	0.2	0.3	0.2	0.2
9650-9655, 9659, 9661-9665, 9667 Classical Hodgkin's Lymphoma, total	12,045	5.1	63.9	19.6	11.4	7.2	8.3	8.5	8.4	13.0
Mature B-cell neoplasms	89,556	0.4	11.2	40.1	48.3	65.9	60.3	74.6	67.9	60.5
9670, 9823 Chronic lymphocytic leukemia/small lymphocytic lymphoma	22,871	0.1	5.2	39.8	54.9	14.4	16.7	15.2	16.4	19.8
9671, 9760-9762 Immunoproliferative diseases	4,128	0.1	7.8	39.7	52.4	4.1	2.1	4.0	3.4	3.6
9673 Mantle cell lymphoma	2,055	0.1	10.7	45.6	43.6	1.7	1.2	1.8	1.8	1.5
9690, 9691, 9695, 9698 Follicular lymphoma	9,392	0.2	22.7	48.5	28.6	7.8	7.2	8.8	5.4	4.1
9675, 9678-9680, 9684 Diffuse large B-cell lymphoma	18,685	0.6	18.4	38.4	42.6	10.3	11.2	20.3	16.0	9.6
9687, 9826 Burkitt's lymphoma	949	24.2	39.1	23.1	13.6	1.1	0.5	1.2	0.7	0.5
9689, 9699, 9764 Marginal zone lymphoma	1,995	0.1	15.7	43.7	40.5	2.2	0.5	2.6	2.7	0.5
9731-9734 Plasma cell neoplasms	28,064	0.0	6.0	38.1	55.9	23.1	20.0	19.4	20.5	20.0
9833 B-cell polymphocytic leukemia	14	7.1	0.0	28.6	64.3	0.1	0.0	0.0	0.0	0.0
9940 Hairy cell leukemia	1,403	0.0	27.7	46.1	26.2	1.1	0.9	1.4	1.0	1.0
Mature T-cell and NK-cell neoplasms	5,149	1.7	23.0	40.4	34.9	3.7	3.2	4.7	4.8	1.9
9700, 9701, 9709, 9718 9708 T cutaneous lymphoma	2,620	0.8	20.7	41.3	37.2	1.2	1.8	1.3	3.1	0.9
9702, 9705, 9714, 9716, 9717, 9948, 9719, 9827, 9831, 9834 Other T and NK-cell lymphomas	2,529	2.7	25.4	39.5	32.4	2.5	1.4	3.4	1.7	1.0
Precursor cell neoplasms	6,206	52.5	25.7	11.7	10.1	5.1	4.5	4.5	3.8	6.1
9727-9729, 9835-9837 Precursor cell neoplasms, B, T and NOS										
Unknown type of lymphoid neoplasm (NOS), total	25,236	1.4	14.4	36.3	47.9	17.6	23.6	7.2	15.0	18.2
9590 Lymphoma NOS ¹	9,149	1.1	14.5	35.3	49.1	1.4	10.0	1.3	4.3	8.7
9591 Non Hodgkin's lymphoma, NOS ¹	15,285	1.4	14.8	37.0	46.8	16.0	13.1	5.4	10.2	7.7
9820, 9832 Lymphatic leukemia, NOS ¹	802	2.7	8.5	33.8	55.0	0.2	0.5	0.5	0.5	1.9
Lymphoid neoplasms, total number of cases	138,581	3.4	17.6	36.3	42.7	7.4	45.3	14.5	24.1	8.7

¹NOS: not otherwise specified. Composite Hodgkin's and non-Hodgkin's lymphoma are not reported because of low number of cases.